Advertisement
Abstract| Volume 46, SUPPLEMENT 2, e26, January 2018

Zonisamide improves Parkinsonism in Dementia with Lewy Bodies (DLB): A randomized double-blind placebo-controlled Phase 3 study

DOI:https://doi.org/10.1016/j.parkreldis.2017.11.085
Zonisamide improves Parkinsonism in Dementia with Lewy Bodies (DLB): A randomized double-blind placebo-controlled Phase 3 study
Previous ArticleAn electrical muscle stimulation therapy for intractable tremor in Parkinson’s disease: a randomized sham-controlled trial of a tremor’s glove device
Next ArticleCooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism
      Objective: To verify the efficacy of zonisamide for parkinsonism in dementia with Lewy bodies (DLB).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      OP-5-11

      Identification

      DOI: https://doi.org/10.1016/j.parkreldis.2017.11.085

      Copyright

      © 2017 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX